Respiratory syncytial virus disease severity is associated with distinct CD8\u3csup\u3e+\u3c/sup\u3e T-cell profiles by Siefker, David T. et al.
Louisiana State University 
LSU Digital Commons 
Faculty Publications Department of Biological Sciences 
2-1-2020 
Respiratory syncytial virus disease severity is associated with 
distinct CD8+ T-cell profiles 
David T. Siefker 
School of Veterinary Medicine 
Luan Vu 
School of Veterinary Medicine 
Dahui You 
University of Tennessee Health Science Center 
Andrew McBride 
University of Tennessee Health Science Center 
Ryleigh Taylor 
University of Tennessee Health Science Center 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs 
Recommended Citation 
Siefker, D., Vu, L., You, D., McBride, A., Taylor, R., Jones, T., DeVincenzo, J., & Cormier, S. (2020). Respiratory 
syncytial virus disease severity is associated with distinct CD8+ T-cell profiles. American Journal of 
Respiratory and Critical Care Medicine, 201 (3), 325-334. https://doi.org/10.1164/rccm.201903-0588OC 
This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital 
Commons. For more information, please contact ir@lsu.edu. 
Authors 
David T. Siefker, Luan Vu, Dahui You, Andrew McBride, Ryleigh Taylor, Tamekia L. Jones, John DeVincenzo, 
and Stephania A. Cormier 
This article is available at LSU Digital Commons: https://digitalcommons.lsu.edu/biosci_pubs/834 
ORIGINAL ARTICLE
Respiratory Syncytial Virus Disease Severity Is Associated with
Distinct CD81 T-Cell Profiles
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John DeVincenzo2,3, and Stephania A. Cormier1
1Department of Biological Sciences, College of Science, and Department of Comparative Biomedical Sciences, School of Veterinary
Medicine, Louisiana State University, Baton Rouge, Louisiana; 2Department of Pediatrics, and 4Department of Preventive Medicine,
University of Tennessee Health Science Center, Memphis, Tennessee; and 3Children’s Foundation Research Institute, Le Bonheur
Children’s Hospital, Memphis, Tennessee
ORCID ID: 0000-0002-6050-6172 (S.A.C.).
Abstract
Rationale: Respiratory syncytial virus (RSV) causes significant
morbidity and mortality in infants worldwide. Although T-helper
type 2 (Th2) cell pathology is implicated in severe disease, the
mechanisms underlying the development of immunopathology are
incompletely understood.
Objectives:We aimed to identify local immune responses associated
with severe RSV in infants. Our hypothesis was that disease severity
would correlate with enhanced Th2 cellular responses.
Methods: Nasal aspirates were collected from infants hospitalized
with severe (admitted to the pediatric ICU) ormoderate (maintained
in the general ward) RSV disease at 5 to 9 days after enrollment. The
immune response was investigated by evaluating T-lymphocyte
cellularity, cytokine concentration, and viral load.
Measurements and Main Results: Patients with severe disease
had increased proportions of CD8 (cluster of differentiation 8)-
positive T cells expressing IL-4 (Tc2) and reduced proportions of
CD81 T cells expressing IFNg (Tc1). Nasal aspirates from patients
with severe disease had reduced concentrations of IL-17. Patients
with greater frequencies of Tc1, CD81 T cells expressing IL-17
(Tc17), and CD41 T cells expressing IL-17 (Th17) had shorter
durations of hospitalization.
Conclusions: Severe RSV disease was associated with distinct T-cell
profiles. Tc1, Tc17, and Th17 were associated with shorter hospital
stay and may play a protective role, whereas Tc2 cells may play a
previously underappreciated role in pathology.
Keywords: RSV; infant; adaptive; immunity
At a Glance Commentary
Scientific Knowledge on the Subject: Most infants with
respiratory syncytial virus are infected by their second birthday.
Despite known risk factors, such as prematurity and congenital
heart disease, most hospitalized infants are previously healthy.
The mechanisms underlying the immunopathology of severe
disease are incompletely understood.
What This Study Adds to the Field: Severe respiratory
syncytial virus disease was associated with increased IL-4–
expressing CD8 (cluster of differentiation 8)-positive T cells
and reduced IFNg–expressing T cells in nasal aspirates. IL-17
concentration in nasal aspirates was reduced in patients with
severe disease, and patients with lower frequencies of IL-17–
producing T cells had longer durations of hospitalization.
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Respiratory syncytial virus (RSV) is the number
one cause of lower respiratory infections in
children (1) and hospitalization with severe
RSV disease in infancy is linked to asthma
development later in life (2). There are no
vaccines or specific therapeutics available, and
prophylactic treatment with palivizumab is
approved for high-risk infants only (3).
Although there are known risk factors for
severe RSV disease, such as prematurity,
,6 months of age upon initial infection, and
congenital heart disease, the majority of infants
who are hospitalized are previously healthy
without known risk factors (4). Studies have
suggested a role for immune dysfunction in
RSV disease severity. Nasal lavages of infants
with RSV bronchiolitis exhibit a greater
IL-4/IFNg ratio compared with infants
without RSV bronchiolitis (5), suggesting a
role for T-helper type 2 (Th2) (CD4 [cluster of
differentiation 4]-positive IL-41 T cells) in
immunopathology. Disease severity in infants
hospitalized with RSV has been shown to
correlate with the level of immunoregulatory
IL-10–expressing B cells, which dampen
protective Th1 responses, in the
nasopharyngeal aspirate (6). Nasopharyngeal





n= 24 P Value
Age at admission, d, median (range) 69 (13–362) 87 (11–357) 0.749
Birthweight, g, median (range) 2,977 (794–4,139) 2,821 (1,219–4,309) 0.5355
Sex, n (%) 0.4092
F 14 (37) 6 (25)
M 24 (63) 18 (75)
Race, n (%) 0.0779
White 7 (18) 10 (42)
African American and Hispanic 31 (82) 14 (58)
Birthplace, n (%) 0.4097
Neonatal ICU 11 (29) 10 (42)
Well-baby nursery 27 (71) 14 (58)
Premature, n (%) 0.4286
No 24 (63) 12 (50)
Yes 14 (37) 12 (50)
Gestational age, wk, median (range) 38 (24–41) 36.5 (29–40) 0.3842
Breastfed, n (%) 0.1139
No 20 (53) 7 (29)
Yes 18 (47) 17 (71)
Exposure to tobacco*, n (%) 1
No 28 (74) 18 (75)
Yes 10 (26) 6 (25)
Daycare, n (%) 0.5111
No 32 (84) 18 (75)
Yes 6 (16) 6 (25)
Delivery, n (%) 1
Cesarean 14 (37) 9 (38)
Vaginal 24 (63) 15 (62)
Family history of asthma, n (%) 0.0683
No 14 (37) 15 (63)
Yes 24 (63) 9 (37)
Oxygen supplementation, n (%) 0.0043
No 11 (29) 0 (0)
Yes 27 (71) 24 (100)
Mechanically ventilated, n (%) <0.0001
No 38 (100) 8 (33)
Yes 0 (0) 16 (67)
RSV strain†, n (%) 0.39
A 16 (47) 12 (63)
B 18 (53) 7 (37)
LOS, d, median (range) 5 (2–11) 15 (7–103) <0.0001
Duration of fever, d, median (range) 1 (0–5) 1 (0–6) 0.8185
Duration of congestion, d, median (range) 4 (1–14) 3 (0–14) 0.4492
Duration of increased work of breathing, d, median
(range)
2 (0–14) 2 (0–6) 0.4043
Duration of cough, d, median (range) 4 (1–10) 3 (0–14) 0.3343
RSV viral load†, log TCID50/ml, median (range) 6.29 (3.73–7.63) 6.47 (5.05–7.71) 0.3404
Definition of abbreviations: LOS= length of stay; RSV= respiratory syncytial virus; TCID50/ml = 50% tissue culture infectious dose per milliliter.
Patient demographics and clinical information by pediatric ICU status. Statistical significance was determined by Fisher’s exact test for categorical data
and Mann Whitney test for continuous data. No adjustment was made for multiple testing. P values for continuous data were computed by Mann-Whitney
test. P values for categorical data were computed by Fisher’s exact test. Bold indicates P,0.05.
*Any household member smokes.
†Unknown data not accounted for in analyses.
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aspirates have also been shown to contain
enhanced proinflammatory cytokines such as
IL-6 and IL-8 (7–9), which may contribute
to the development of pathogenic CD41
expressing IL-17 (Th17) responses.
Furthermore, infants hospitalized with a severe
episode of RSV disease maintain high levels
of proinflammatory cytokines in their
nasopharyngeal aspirates 1 year after
hospitalization, with 85% of infants suffering
at least one wheezing incident (10). Despite
strong evidence that severe RSV disease is
caused by a dysfunctional immune response
and animal studies that suggest a role for
Th2 cells in immunopathology, there have
been few studies looking at the cellular
immune response to RSV in the nasal
mucosa of human infants.
Here, for the first time, we present data
comparing the mucosal T-cell immune
responses of infants hospitalized with RSV
disease of varying severity. We tested the
hypothesis that patients admitted to the
pediatric ICU (PICU; severe) would have a
greater proportion of Th2 cells in their nasal
aspirates compared with patients admitted
to the general ward (moderate). This study
reveals that RSV disease severity is associated
with a specific T-cell profile and that CD81
T cells expressing IL-4 (Tc2) cells may play
an important, underappreciated role in the
development of RSV immunopathology.
Methods
Study Design
Infants hospitalized with a positive RSV
quantitative PCR result in Le Bonheur
Children’s Hospital, Memphis, Tennessee,
during the respiratory seasons of 2014 to
2017 were enrolled in this study. Patients
who were admitted to or transferred to the
PICU within 10 days of hospital admission
were defined as having severe disease, while
those admitted to the general floor were
defined as having moderate disease.
Nasal aspirates were collected from 62
patients at day of enrollment for viral load
determination and between 5 and 9 days
after enrollment for flow cytometry and
cytokine analysis. At this later time point,
some patients had been discharged and
returned to the hospital for sample
collection. Of the 62 patients who provided
samples up to this time point, 24 patients
had disease severe enough for admission
to the PICU and 38 patients with
moderate disease were maintained on the
general ward (see Figure E1 in the online
supplement).
Sample Collection
Nasal aspirates were collected by trained
study personnel using a standardized
method described previously (11). Cell and
supernatant isolation are described in the
online supplement.
Flow Cytometry
Cell staining is described in detail in the online
supplement. Signature cytokine expression
was used to classify nasal aspirate T cells, and
gating on cytokine positive populations
was set based on fluorescence minus one
controls (see Figures E2 and E3). Within the
live CD31CD41 population, T cells were
defined as Th1 (IFNg1IL-42IL-172), Th2
(IFNg2IL-41IL-172), and Th17
(IFNg2IL-42IL-171). Within the live
CD31CD81 population, T cells were
defined as T cells expressing IFNg
(Tc1) (IFNg1IL-42IL-172), Tc2
(IFNg2IL-41IL-172), and CD81 T cells
expressing IL-17 (Tc17) (IFNg2IL-42IL-171).
Samples with less than 100 CD41 or
CD81 T cells were excluded from further
analyses.
Real-Time RT-PCR
Viral RNA was extracted from cell-free
fractions of nasal aspirates collected on
the day of enrollment using QIAamp
Viral RNA kit (Qiagen). Viral load was
interpolated by qRT-PCR from a standard
curve produced from an RSV stock at
known concentration in 50% tissue
culture infectious dose per milliliter.
Details are provided in the online
supplement.
Multiplex Cytokine Analysis
Cell-free supernatants from nasal aspirates
were evaluated for IFNg, IL-4, IL-13, and
IL-17A concentrations using the Luminex
technology multiplex cytokine kit, Milliplex
Human High Sensitivity T-cell Panel
(EMD Millipore) with a BioPlex 200
instrument (Bio-Rad). Samples with
cytokine concentrations below the limit of
detection of the assay were replaced by a
value equal to the limit of detection divided
by the square root of 2 (12).
Statistical Analysis
Frequencies and percentages were used to
summarize categorical data, whereas median
and interquartile ranges were used to describe
continuous data. Comparison of patient
demographics, clinical characteristics, and
cellular and cytokine responses in nasal
aspirates were tested using Fisher’s exact test
for categorical data and the Mann-Whitney
test for continuous data. Luminex
coefficients were computed to examine the
association between clinical data. All data
were considered statistically significant at
P, 0.05. Bivariate analysis was used to
determine statistical differences in T-cell
subsets between patients with moderate
disease and patients with severe disease.
Statistical analyses were performed using









































Figure 1. Patients with severe disease have a CD8 (cluster of differentiation 8)-skewed T-cell
response. Nasal aspirates from infants collected 1 week after enrollment were analyzed by flow
cytometry. (A and B) The percentages of CD41 and CD81 T cells (A) and the ratio of CD81/CD41
T cells (B) are compared between patients with moderate disease (n=31) and patients with severe
disease (n=16). **P,0.01 by bivariate analysis.
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Results
Characteristics of the Study
Population
As expected, infants with severe disease were
more likely to require supplemental oxygen
(P=0.0043) or mechanical ventilation
(P,0.0001) compared with patients with
moderate disease (Table 1). Furthermore,
patients with severe disease required a
significantly longer length of hospital
stay (median, 15 d) compared with patients
with moderate disease (median, 5 d;
P, 0.0001). Importantly, there was no
difference in symptom duration (fever,
congestion, increased work of breather,
or cough) before enrollment between
patients with severe disease and patients
with moderate disease.
Severe Disease Is Associated with
Type 2–Skewed CD8 T-cell Response
This study aimed to characterize the
mucosal T-cell response in infants
hospitalized with RSV. Our cohort of infants
was enrolled at a median of 2 to 3 days after
symptom onset (see Table 1); therefore, we
chose to investigate T-cell profiles in
patients at 5 to 9 days after enrollment.
We first compared the frequencies of
CD31CD41 and CD31CD81 T cells in
nasal aspirates between patients
with moderate disease and patients with
severe disease. Fifteen patients (seven
moderate and eight severe) were excluded
from flow cytometry analysis due to low
recovery of nasal aspirate cells. Patients with
severe disease had a significantly higher
proportion of CD81 T cells (median, 78.05%)
compared with patients with moderate
disease (median, 56.4%; P=0.0017)
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Figure 2. Patients with severe disease have a greater frequency of CD8 (cluster of differentiation 8)-positive T cells expressing IL-4 (Tc2) and reduced
frequency of CD81 T cells expressing IFNg (Tc1) than patients with moderate disease. A Boolean analysis was done of cytokine expression in T cells in
nasal aspirates of patients with moderate (n=31) and severe respiratory syncytial virus disease (n=16). (A) CD31 CD81 T cells (*P, 0.05 by bivariate
analysis) and (B) CD31 CD41 T cells. (C) Spearman’s correlation coefficients were determined between clinical characteristics and T-cell subsets (n=47
patients). (D) Spearman’s correlation coefficients were determined between viral load and T-cell subsets. At day of enrollment (n=42 patients) the viral
load could not be determined owing to lack of samples for 5 patients for whom T-cell frequency is known. At 5 to 9 days after enrollment (n=36 patients)
viral load could not be determined owing to lack of samples for 8 patients and was undetectable in samples for 3 patients. Dotted lines represent the 95%
confidence interval. Only significant correlations are shown. P,0.05 by Spearman’s correlation coefficient. Tc17=CD8+ T cells expressing IL-17; TCID50/
ml = 50% tissue culture infectious dose per milliliter; Th17=CD4+ T cells expressing IL-17.
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disease had a significantly lower frequency of
CD41 T cells (median, 14.3%) compared
with patients with moderate disease (median,
27%; P=0.0062). Next, we evaluated
the ratio of CD81/CD41 T cells within each
patient. We found that patients with severe
disease had a greater CD81/CD41 T-cell
ratio (median, 5.63) compared with patients
with moderate disease (median, 1.9;
P=0.0049) (see Figure 1B).
Our initial hypothesis was that severe
disease would be associated with a Th2-
biased cellular response in nasal aspirates.
However, patients with severe disease had
significantly increased frequencies of Tc2
cells (median, 40.1%) compared with
patients with moderate disease (median,
14.4%; P= 0.033). Patients with severe
disease also had significantly reduced
frequencies of Tc1 cells (median, 12.51%)
compared with patients with moderate
disease (median, 26.9%; P= 0.0261)
(Figure 2A and Table E1). An analysis of
the CD31CD41 subsets revealed an
increase in frequency of Th2 cells in
patients with severe disease (median,
14.8%) compared with patients with
moderate disease (median, 7.7%),
although this difference did not reach
significance. Patients with moderate
disease and patients with severe disease
had similar frequencies of all other CD41
subsets (see Figure 2B). Gestational age
was positively correlated with the
frequency of Tc17 cells, whereas
birthweight was positively correlated
with the frequency of Th2 cells.
Additionally, the age at hospital
admission was positively correlated
with the frequency of Tc1 and Th17
cells (see Figure 2C). There were no
significant correlations with the other
T-cell subsets (data not shown). Patients
with lower viral load at the day of
enrollment had greater frequencies of
Tc17 and Th17 cells. Additionally,
patients with lower viral load at 5 to
9 days after enrollment had greater
frequencies of Tc1 cells and a lower
ratio of IL-41 T cells/IFNg1 T cells
(see Figure 2D). There were no significant
correlations between viral load and the
other T-cell subsets (data not shown).
There was a greater ratio of type 2/type 1
T cells in patients with severe disease
(median, 1.29) compared with patients
with moderate disease (median, 0.72;
P = 0.0368 by Mann-Whitney test);
however, this did not reach significance
after adjusting for confounders
(P = 0.5758) (Figure 3A). Within the
CD81 fraction, patients with severe
disease had greater Tc2/Tc1 ratios
(median, 1.54) compared with patients
with moderate disease (median, 0.70;
P = 0.0202 by Mann-Whitney test);
however, this did not reach significance
after adjusting for confounders
(P = 0.1672) (see Figure 3B). There was
no difference in the Th2/Th1 ratio
between patients with moderate disease
and patients with severe disease (see
Figure 3C). Further investigation
of the CD31CD81 subset revealed an
association between the level of CD8
expression and the cytokine produced.
CD31CD81 T cells diverged into
two separate populations based on CD8
expression (Figure 4). A gate around the
total CD81 population includes cells
expressing IL-4 (Tc2), IFNg (Tc1), and
IL-17 (Tc17) (see Figure 4A). However,
two populations appeared to exist within
the total CD81 gate based on CD8
expression. We found that cells expressing
high levels of CD8 predominantly
produced IFNg, whereas those expressing
low levels of CD8 produced predominantly
IL-4 or IL-17 (see Figure 4B).
Tc1, Tc17, and Th17 Cell Subsets Are
Associated with Shorter Hospital
Length of Stay
As previously described, hospital length of
stay was significantly greater in patients
with severe disease compared with
patients with moderate disease (see
Table 1). To further investigate whether
frequencies of T-cell subsets are
associated with disease severity, we
examined whether the frequency of T-cell
subsets correlated with length of stay.
Within the CD81 compartment, Tc1 and
Tc17 subsets were negatively correlated
with length of stay (r =20.4333;
P = 0.0023 and r =20.3415; P = 0.0188,
respectively). In contrast, Tc2 cells were
positively correlated with length of stay;
however, this relationship did not reach
statistical significance (r = 0.2549;
P = 0.0838) (Figure 5A). Within the CD41
compartment, Th17 cells were also
negatively correlated with length of
stay (r =20.2955; P = 0.0437) (see
Figure 5B).
Patients with Severe Disease Have
Reduced IL-17 Concentrations in
Nasal Aspirates
We tested the hypothesis that type 2
cytokine concentrations would be greater in
the nasal aspirate supernatants of patients
with severe disease compared with patients
with moderate disease. Surprisingly, despite
greater frequency of type 2 T cells in nasal
aspirates of patients with severe disease, the
concentration of the type 2 cytokines IL-4
and IL-13 were similar among patients with
moderate disease and patients with severe
disease. There was also no difference in the
type 1 cytokine IFNg between patients with
moderate disease and patients with severe
disease. Interestingly, however, patients
with severe disease had significantly
reduced IL-17 concentrations (median,
0.592 pg/ml) compared with patients with
moderate disease (median, 1.262 pg/ml;
P= 0.0086) (Figure 6). We also asked
whether the frequency of T-cell subsets


























































Figure 3. Patients with severe disease have a type 2–skewed T-cell response. (A) Ratio of
IL-41/IFNg1 T cells, (B) ratio of CD81 (cluster of differentiation 8–positive) T cells expressing IL-4
(Tc2)/CD81 T cells expressing IFNg (Tc1), and (C) ratio of Th2/Th1 in nasal aspirates from infants
with moderate and severe respiratory syncytial virus disease (n= 31) and patients with severe
disease (n= 16). *P, 0.05 by Mann-Whitney test. Th = T-helper cell.
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concentrations in nasal aspirates. Within
the CD81 subset, the frequency of Tc17
cells had a positive correlation with the
concentration of IL-17 (r= 0.3092;
P= 0.0463). In contrast, Tc1, Tc2, and all
Th subsets were not correlated with their
signature cytokine concentrations (see
Figure E4).
Discussion
Many studies describe the immune response
to RSV as type 2–biased (5, 13–16). It is
controversial, however, whether the level of
type 2 cytokines (IL-4, IL-5, and IL-13) or
proportions of type 2 cytokine–producing
cells (Th2 and Tc2) are associated with
varying severity of disease. Here, we tested
the hypothesis that patients admitted to the
PICU would have a greater proportion of
Th2 cells in nasal aspirates compared with
patients admitted to the general ward.
Indeed, our results showed a greater
proportion of IL-41 T cells in patients
with severe disease; however, statistical
significance was reached only in the CD81
fraction. In the CD41 fraction, IL-41
T cells were increased in patients with
severe disease compared with patients with
moderate disease; however, this difference
did not reach significance. Two studies have
shown enhanced IL-4/IFNg ratios in nasal
aspirates in patients with more severe RSV
disease (5, 13). In our study there was no
difference in the IL-4/IFNg ratio, which
might be a result of the late time point after
the decline of these cytokines. Of course, we
only evaluated one time point in this study
and it is possible that the peak CD4
response has already occurred. It has been
shown that CD4 responses occur before
CD8 (17). Because patients often arrive
in the hospital days after the onset of
symptoms it is impossible to know when
the patients were infected. This ambiguity
in the time of infection could result in
analysis at a later time point dominated by
CD8 responses. Nevertheless, a pathogenic
role for CD81 T cells is also supported by
mouse models of RSV infection (18).
Depletion of CD81 cells reduces illness in
mice after primary RSV infection (19), and
adoptive transfer of an RSV-specific
cytotoxic T lymphocyte clone both
exacerbated lung pathology in mice and
mediated viral clearance (20). On the other
hand, fatal cases of RSV infection in human
infants show few lymphocytes (neither
CD81 nor CD41) by immunohistostaining
of postmortem lung tissue (21, 22).
Importantly, cytokine staining was not
performed, and it is possible that these
patients succumbed to infection before
lymphocyte recruitment. Indeed, IL-4–
expressing CD81 T cells have been found
in the blood after RSV infection, but their
proportions are negatively correlated with
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Figure 4. Level of CD8 (cluster of differentiation 8) expression correlates with cytokine production. (A)
T cells expressing IFNg (Tc1), T cells expressing IL-4 (Tc2), and CD81 T cells expressing IL-17 (Tc17)
cells distinguished based on cytokine expression within the total CD81 gate. (B) The majority of Tc1
cells exhibit high levels of CD8 expression, whereas the majority of Tc2 and Tc17 cells exhibit low
CD8 expression. (C) Comparison of CD8 median fluorescence intensity in Tc1, Tc2, and Tc17 cells as
defined in A. A representative sample is shown. MFI =median fluorescence intensity.
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reduction in systemic Tc2 cells in severe
RSV disease is a result of relocation to the
respiratory tract. It has been shown that
Tc2 cells induced by HIV infection have
reduced cytotoxic activity (24). Future
directions will include characterization of
the Tc2 cells found in patients with severe
RSV disease, such as activation status and
cytotoxic activity. Altogether, these results
suggest an important role for Tc2 cells in
the severity of RSV disease.
Many studies attribute IL-4 protein
detected in BAL fluid, nasal aspirates, or
peripheral blood to a Th2 response (25–27).
This study reveals CD81 T cells as an
important source of IL-4 production in
RSV-infected infants. It has been shown in
mice that Th2 responses to lymphocytic
choriomeningitis virus infection cause
virus-specific CD81 T cells to switch from
IFNg production to IL-5 production (Tc1
to Tc2 switch) (28). Furthermore, these Tc2
cells mediated eosinophil recruitment to the
lungs upon lymphocytic choriomeningitis
virus peptide challenge. It is possible that in
human infants an initial Th2 response
induces a robust Tc2 response, and both
T-cell compartments synergize to establish
severe disease.
It was also observed that Tc2 cells in
nasal aspirates of RSV patients expressed
lower levels of CD8 than Tc1 cells (see
Figure 4). Reduced CD8 expression in
T cells has been associated with activation,
reduced antigen sensitivity (29), and
reduced degranulation (30). In a macaque
model of acute simian immunodeficiency
virus infection, antigen-specific CD81
could also be separated into CD8high and
CD8low populations (31). Importantly, the
CD8low population produced less IFNg
compared with the CD8high population,
similar to what we observe in human
infants with RSV. Unfortunately,
production of IL-4 was not tested in this
model. However, it has been shown in mice
that IL-4 reduces RSV-specific cytolytic
activity and delays viral clearance (32). In
fact, we found reduced proportions of Tc1
cells in patients with severe disease
compared with patients with moderate
disease (see Figure 2A). Additionally, CD8
T cells activated under type 2 conditions
produce IL-4 while downregulating CD8
expression, granzyme B, and IFNg in vitro
(33). Further studies will determine
differences in the phenotypes of Tc1 versus
Tc2 cells in nasal aspirates from RSV-
infected infants.
Higher frequencies of Tc2 cells and
lower frequencies of Tc1 cells were
associated with admission to the PICU in
patients hospitalized with RSV. This
prompted us to ask whether the frequencies
of T-cell subsets are also associated with the
total length of hospital stay. Indeed, Tc1,
Tc17, and Th17 frequencies were negatively
correlated with length of stay, suggesting
that these cell types and/or their effector
cytokines IFNg and IL-17 confer protection
to RSV disease (see Figure 5). Likewise,
IL-17 concentration was significantly lower
in patients with severe disease compared
with moderate disease (see Figure 6). These
results suggest a protective effect for IL-17
and are supported by a previous study that
observed decreased IL-17 concentrations
in nasal aspirates of ventilated infants
compared with nonventilated infants at the
time of hospital discharge (34).
Although the frequency of Tc17 cells
was significantly correlated with IL-17
concentrations in the nasal aspirates,
overall, the frequencies of T-cell subsets
were not correlated with their signature
















































































































Figure 5. CD81 T cells expressing IFNg (Tc1), CD81 T cells expressing IL-17 (Tc17), and CD41
T cells expressing IL-17 (Th17) cell subsets are associated with shorter hospital length of stay. (A–B)
Spearman’s correlation coefficients (r) were determined between hospital length of stay and
frequency of nasal aspirate Th1 (CD31CD41IFNg1), T-helper cell type 2 (Th2) (CD31CD41IL-41),
and Th17 (CD31CD41IL-171) (A); and Tc1 (CD31CD81IFNg1), T cells expressing IL-4 (Tc2)
(CD31CD81IL-41), and Tc17 (CD31CD81IL-171) (B). n=47 patients. Dotted lines represent
the 95% confidence interval. P, 0.05 by Spearman’s correlation coefficient.
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cytokine concentrations (see Figure E4).
The lack of correlation may be due to the
time point analyzed. As previously noted, it
has been shown that IL-17 concentrations
are higher later in the course of infection in
patients with moderate disease. Indeed,
IL-17 and IFNg were detectable in the
majority of patients (88%) at 5 to 9 days
after enrollment, regardless of disease
severity. In contrast, only 47% of patients
had detectable IL-4, and 32% had detectable
IL-13 levels at this time point. Therefore, our
time point may be appropriate to compare
frequencies of T-cell subsets that express
their signature cytokines after stimulation ex
vivo but too late to detect these cytokines in
the nasal aspirate supernatant. Another
possibility that may explain the discrepancy
between the frequency of T-cell subsets and
their signature cytokine concentration in the
nasal aspirate is that the multiple cell types
may be responsible for the overall cytokine
concentration.
There are conflicting reports in the
literature regarding whether viral load is
associated with disease severity. Many
reports show a positive correlation between
viral load and disease severity (11, 35–37).
However, some studies report that disease
severity is not associated with viral load (13,
38, 39). Recently, it was reported that viral
load is lower in patients with severe
compared with moderate disease when
adjusted for symptom duration (40).
Discrepancies within the literature are likely
the result of differences in characterization
of disease severity, patient demographics,
variability in the time after symptom
onset that sampling occurs, sampling
method, and even method of viral load
determination. In this study, admission to
the PICU versus general ward was not
associated with viral load at the day of
enrollment or the day of flow cytometry
analysis (see Figure E5). However, patients
with lower viral load at the day of enrollment
had increased frequencies of Tc17 and Th17
cells, and patients with lower viral load at
5 to 9 days after enrollment had higher
frequencies of Tc1 and a reduced ratio of total
IL-41/IFNg1 T-cell cells (see Figure 2D).
Likewise, it has been shown in experimental
RSV infection of adults that RSV-specific
CD81 T cells are inversely correlated with
viral load (41).
We acknowledge that, in contrast to
our results, there are a number of reports
indicating a correlation between age and
disease severity. The majority of those
reports use hospitalization as the definition
of severe disease and some include children
over the age of 12 months (42–46). In
contrast, our study involved only hospitalized
infants (,1 yr of age). Additionally, 53 out of
62 (85.5%) of our patient population were less
than 6 months of age. Of the studies using the
same definition of severity (i.e., PICU versus
ward) and comparing children of similar
age, one failed to demonstrate a correlation
with age and severity (11, 47–50). We
do not understand the reasons for these
discrepancies, but we reiterate that differences
in characterization of disease severity,
differences in patient demographics,
variability in the time after symptom onset
that sampling occurs, sampling method, and
even method of viral load determination exist
across these studies and could be responsible
for the different outcomes.
This study has some limitations. This
study was performed in a predominantly
African American population. In our study,
African Americans had significantly
reduced Tc2 cells compared with white
individuals (see Table E2). These results are
in line with a previous study showing that
African Americans in Tennessee are less
likely to be hospitalized for bronchiolitis
within the first year of life compared with
white individuals (51). A multicenter study
that includes areas of multiple racial
backgrounds would provide a more
comprehensive picture of RSV disease
among genetically diverse populations.
Additionally, disease severity is a subjective
classification. Here, we chose to define
severe disease as admission to the PICU.
However, the majority of patients with
moderate disease required supplemental
oxygen (71.1%). Characterization of disease
severity by PICU status could be refined
further by incorporating objective clinical
parameters to determine severity. Several
severity scoring methods have been used to
categorize infants with varying disease
severity (52–59). The adoption of a single,
standardized RSV severity scoring system
would allow better comparisons between
studies performed by different groups.
Interestingly, Tc2 and Th2 cells were
significantly higher in patients on oxygen
supplementation. Another limitation is our
small sample size. Out of 243 infants
enrolled between 2014 and 2017 over three
respiratory seasons, only 62 patients
provided samples out to the 5 to 9
days after the enrollment time point.
Furthermore, only 24 of these patients were
admitted to the PICU. Additionally, some
nasal aspirates could not be analyzed by
flow cytometry due to low numbers of
live lymphocytes. Statistically significant


































































Figure 6. Lower IL-17 levels are observed in the nasal aspirates of patients with severe disease. Cytokine concentrations in the cell-free nasal aspirates
were compared between patients with moderate and severe respiratory syncytial virus disease. Undetectable samples were set to the limit of detection
divided by the square root of 2 (12). Cell-free nasal aspirates were not available for analysis from 3 patients with moderate disease (n=35) and 5 patients
with severe disease (n=19). **P, 0.01 by Mann-Whitney test.
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patients were found despite our small
sample size.
Conclusions
This study suggests that a specific mucosal
T-cell subset may contribute to severe RSV
disease. To our knowledge, this is the first
study to directly evaluate cytokine-
producing T cells in nasal aspirates.
These results show that RSV disease
severity is associated with a specific
immune profile and suggest a role for
CD81 T cells in the development of RSV
immunopathology. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
Acknowledgment: The authors thank Lisa
Harrison, Beth Meals, Jackie Blanch, and Ryan
Tomlinson for patient enrollment and sample
collection.
References
1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al.
Global burden of acute lower respiratory infections due to respiratory
syncytial virus in young children: a systematic review and meta-
analysis. Lancet 2010;375:1545–1555.
2. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S,
Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis
in infancy and asthma and allergy at age 13. Am J Respir Crit Care
Med 2005;171:137–141.
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody,
reduces hospitalization from respiratory syncytial virus infection in high-
risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531–537.
4. Dawson-Caswell M, Muncie HL Jr. Respiratory syncytial virus infection
in children. Am Fam Physician 2011;83:141–146.
5. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1
and type 2 cytokine imbalance in acute respiratory syncytial virus
bronchiolitis. Am J Respir Crit Care Med 2003;168:633–639.
6. Zhivaki D, Lemoine S, Lim A, Morva A, Vidalain PO, Schandene L,
et al. Respiratory syncytial virus infects regulatory B cells in human
neonates via chemokine receptor CX3CR1 and promotes lung disease
severity. Immunity 2017;46:301–314.
7. Smyth RL, Mobbs KJ, O’Hea U, Ashby D, Hart CA. Respiratory syncytial
virus bronchiolitis: disease severity, interleukin-8, and virus genotype.
Pediatr Pulmonol 2002;33:339–346.
8. Brand HK, Ferwerda G, Preijers F, de Groot R, Neeleman C, Staal FJ,
et al. CD41 T-cell counts and interleukin-8 and CCL-5 plasma
concentrations discriminate disease severity in children with RSV
infection. Pediatr Res 2013;73:187–193.
9. Dı́az PV, Valdivia G, Gaggero AA, Bono MR, Zepeda G, Rivas M,
et al. Pro-inflammatory cytokines in nasopharyngeal aspirate from
hospitalized children with respiratory syncytial virus infection with or
without rhinovirus bronchiolitis, and use of the cytokines as predictors
of illness severity. Medicine (Baltimore) 2015;94:e1512.
10. Pino M, Kelvin DJ, Bermejo-Martin JF, Alonso A, Matı́as V, Tenorio A,
et al. Nasopharyngeal aspirate cytokine levels 1 yr after severe
respiratory syncytial virus infection. Pediatr Allergy Immunol 2009;20:
791–795.
11. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus
load predicts disease severity in previously healthy infants. J Infect
Dis 2005;191:1861–1868.
12. Hornung RW. Estimation of average concentration in the presence of
nondetectable values. Appl Occup Environ Hyg 1990;5:46–51.
13. Caballero MT, Serra ME, Acosta PL, Marzec J, Gibbons L, Salim M,
et al. TLR4 genotype and environmental LPS mediate RSV
bronchiolitis through Th2 polarization. J Clin Invest 2015;125:
571–582.
14. McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA,
Smyth RL. Interleukin 9 production in the lungs of infants with
severe respiratory syncytial virus bronchiolitis. Lancet 2004;363:
1031–1037.
15. Hassan MA, Eldin AM, Ahmed MMT. T - helper2 /T - helper1 imbalance
in respiratory syncytial virus bronchiolitis in relation to disease
severity and outcome. Egypt J Immunol 2008;15:153–160.
16. Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, Ardura J,
Eiros JM, Alonso A, et al. Predominance of Th2 cytokines, CXC
chemokines and innate immunity mediators at the mucosal level
during severe respiratory syncytial virus infection in children. Eur
Cytokine Netw 2007;18:162–167.
17. Hussell T, Openshaw PJ. Intracellular IFN-gamma expression in natural
killer cells precedes lung CD81 T cell recruitment during respiratory
syncytial virus infection. J Gen Virol 1998;79:2593–2601.
18. Schmidt ME, Varga SM. The CD8 T cell response to respiratory virus
infections. Front Immunol 2018;9:678.
19. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte
subsets in the pathogenesis of primary infection and rechallenge
with respiratory syncytial virus in mice. J Clin Invest 1991;88:
1026–1033.
20. Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus
but augment lung pathology in mice infected with respiratory
syncytial virus. J Exp Med 1988;168:1163–1168.
21. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez
K, et al. Severe human lower respiratory tract illness caused by
respiratory syncytial virus and influenza virus is characterized by the
absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis
2007;195:1126–1136.
22. Welliver TP, Reed JL, Welliver RC Sr. Respiratory syncytial virus and
influenza virus infections: observations from tissues of fatal infant
cases. Pediatr Infect Dis J 2008;27(Suppl):S92–S96.
23. Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V,
Drazenovic V, et al. Predominant type-2 response in infants with
respiratory syncytial virus (RSV) infection demonstrated by cytokine
flow cytometry. Clin Exp Immunol 2000;121:332–338.
24. Maggi E, Giudizi MG, Biagiotti R, Annunziato F, Manetti R, Piccinni MP,
et al. Th2-like CD81 T cells showing B cell helper function and
reduced cytolytic activity in human immunodeficiency virus type 1
infection. J Exp Med 1994;180:489–495.
25. Park JS, Kim YH, Kwon E, Callaway Z, Fujisawa T, Kim CK.
Comparison of nasal cytokine profiles of human metapneumovirus
and respiratory syncytial virus. Asia Pac Allergy 2017;7:206–212.
26. Garcı́a C, Soriano-Fallas A, Lozano J, Leos N, Gomez AM, Ramilo O,
et al. Decreased innate immune cytokine responses correlate with
disease severity in children with respiratory syncytial virus and
human rhinovirus bronchiolitis. Pediatr Infect Dis J 2012;31:86–89.
27. Christiaansen AF, Syed MA, Ten Eyck PP, Hartwig SM, Durairaj L,
Kamath SS, et al. Altered Treg and cytokine responses in RSV-
infected infants. Pediatr Res 2016;80:702–709.
28. Coyle AJ, Erard F, Bertrand C, Walti S, Pircher H, Le Gros G. Virus-
specific CD81 cells can switch to interleukin 5 production and
induce airway eosinophilia. J Exp Med 1995;181:1229–1233.
29. Xiao Z, Mescher MF, Jameson SC. Detuning CD8 T cells: down-
regulation of CD8 expression, tetramer binding, and response during
CTL activation. J Exp Med 2007;204:2667–2677.
30. Apte SH, Baz A, Groves P, Kelso A, Kienzle N. Interferon-gamma and
interleukin-4 reciprocally regulate CD8 expression in CD81 T cells.
Proc Natl Acad Sci USA 2008;105:17475–17480.
31. Xu H, Wang X, Lackner AA, Veazey RS. CD8 down-regulation and
functional impairment of SIV-specific cytotoxic T lymphocytes in
lymphoid and mucosal tissues during SIV infection. J Leukoc Biol
2013;93:943–950.
32. Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, Parker
RA, et al. Overexpression of interleukin-4 delays virus clearance
in mice infected with respiratory syncytial virus. J Virol 1997;71:
8672–8677.
33. Harland KL, Day EB, Apte SH, Russ BE, Doherty PC, Turner SJ,
et al. Epigenetic plasticity of Cd8a locus during CD8(1) T-cell
development and effector differentiation and reprogramming. Nat
Commun 2014;5:3547.
ORIGINAL ARTICLE
Siefker, Vu, You, et al.: Mucosal T-Cell Responses to RSV 333
 
34. Faber TE, Groen H, Welfing M, Jansen KJ, Bont LJ. Specific increase
in local IL-17 production during recovery from primary RSV
bronchiolitis. J Med Virol 2012;84:1084–1088.
35. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP.
Respiratory syncytial virus load, viral dynamics, and disease severity
in previously healthy naturally infected children. J Infect Dis 2011;
204:996–1002.
36. El Saleeby CM, Devincenzo JP. Respiratory syncytial virus load and
disease severity in the community. J Med Virol 2011;83:904–905.
37. Hasegawa K, Jartti T, Mansbach JM, Laham FR, Jewell AM, Espinola JA,
et al. Respiratory syncytial virus genomic load and disease severity among
children hospitalized with bronchiolitis: multicenter cohort studies in
the United States and Finland. J Infect Dis 2015;211:1550–1559.
38. Do LA, Bryant JE, Tran AT, Nguyen BH, Tran TT, Tran QH, et al.
Respiratory syncytial virus and other viral infections among children
under two years old in southern Vietnam 2009-2010: clinical
characteristics and disease severity. PLoS One 2016;11:e0160606.
39. Walsh EE, Wang L, Falsey AR, Qiu X, Corbett A, Holden-Wiltse J, et al.
Virus-specific antibody, viral load, and disease severity in respiratory
syncytial virus infection. J Infect Dis 2018;218:208–217.
40. Thwaites RS, Coates M, Ito K, Ghazaly M, Feather C, Abdulla F,
et al. Reduced nasal viral load and IFN responses in infants with
respiratory syncytial virus bronchiolitis and respiratory failure. Am J
Respir Crit Care Med 2018;198:1074–1084.
41. Jozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, et al. RSV-
specific airway resident memory CD81 T cells and differential
disease severity after experimental human infection. Nat Commun
2015;6:10224.
42. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of
respiratory syncytial virus infection for infants from low-income
families in relationship to age, sex, ethnic group, and maternal
antibody level. J Pediatr 1981;98:708–715.
43. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates
of hospitalization for respiratory syncytial virus infection among
children in medicaid. J Pediatr 2000;137:865–870.
44. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial
virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;
143(Suppl):S127–S132.
45. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz
MD. Risk factors for respiratory syncytial virus-associated lower
respiratory illnesses in the first year of life. Am J Epidemiol 1991;133:
1135–1151.
46. Lloyd PC, May L, Hoffman D, Riegelman R, Simonsen L. The effect of birth
month on the risk of respiratory syncytial virus hospitalization in the first
year of life in the United States. Pediatr Infect Dis J 2014;33:e135–e140.
47. Tasker RC, Roe MF, Bloxham DM, White DK, Ross-Russell RI,
O’Donnell DR. The neuroendocrine stress response and severity of
acute respiratory syncytial virus bronchiolitis in infancy. Intensive
Care Med 2004;30:2257–2262.
48. Viguria N, Martı́nez-Baz I, Moreno-Galarraga L, Sierrasesúmaga L,
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